Beijing-based Chinese oncology research and development firm BeiGene (Beijing), Co., Ltd. has completed a new round of financing worth RMB450 million (US$75 million), according to a company announcement. The round includes initial angel and strategic investors, as well as new investors Hillhouse Capital and CITIC Private Equity (CITIC PE), the private equity arm of CITIC […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.